On World Cervical Cancer Elimination Day, WHO called for stronger links between HIV and cervical cancer services. The agency argued that a coordinated, person-centred approach can reduce deaths and improve quality of life. WHO investigators emphasized that prevention, screening, diagnosis and treatment must be timely and accessible for women and girls living with HIV.
A concise operational message followed: integrate services where women already receive care, streamline referrals, and support treatment completion. The source did not provide specific service delivery models or implementation timelines.
Women living with HIV carry a markedly higher burden of cervical cancer. WHO reported a six-fold increased risk of developing cervical cancer compared with women without HIV. Short-term outcomes are also worse: the agency noted an elevated risk of death within 1–2 years after diagnosis and a three-fold greater likelihood of residual tumours after radiotherapy among women living with HIV.
Data indicated that starting or continuing antiretroviral therapy (ART) at the time cervical cancer treatment begins mitigates the mortality difference—when ART is in place, mortality differences were no longer significant. The WHO release did not include granular survival curves, sample sizes, or detailed study methodologies.
Global prevention and detection efforts are accelerating, WHO observed. The African Region—where the burden is highest—recorded that over 50% of girls received at least one dose of HPV vaccine in 2025. Around 133 countries have introduced cervical cancer screening. These figures demonstrate reach, yet WHO flagged the remaining challenge: ensuring these life-saving services reach every woman and girl, including those living with HIV.
WHO did not provide country-by-country breakdowns, nor did it report screening coverage specifically disaggregated by HIV status in the release.
WHO reported active work with the International Agency for Research on Cancer (IARC) to develop a roadmap for the potential inclusion of HPV35 in future vaccines, citing HPV35’s contribution to cervical cancer incidence and deaths—particularly in the African Region. The source described the collaboration but did not publish technical specifications, proposed vaccine constructs, or expected timelines.
The agency also said it will publish a technical policy brief that highlights rapid initiation or continuation of ART, multidisciplinary HIV–cancer care, monitoring for treatment toxicity and drug–drug interactions, supporting patients to complete cancer treatment, and ensuring access to palliative care when needed. The WHO statement did not provide the brief’s release date or full content within this update.
WHO referenced its Global strategy to accelerate the elimination of cervical cancer as the framework for action. The strategy sets interim 2030 targets: 90% HPV vaccination coverage among girls by age 15 years; 70% coverage of screening with a high-performance test; and 90% treatment and care for women identified with cervical cancer and cervical disease. WHO investigators warned that achieving these targets requires focused attention on women living with HIV so they benefit equitably from progress.
The organization urged leveraging long-standing HIV programmes because these platforms reach women repeatedly over many years and can be used for HPV screening and precancer treatment. WHO leaders stated plainly that HIV status must never be a barrier to timely cancer diagnosis and treatment.
WHO also called for the active inclusion of cervical cancer survivors and women living with HIV in designing services, noting that lived experience must inform programmatic design and service delivery priorities.
WHO identified equity and access gaps as central barriers. The agency stressed that women and girls in settings with high HIV prevalence and constrained cancer diagnostic and treatment capacity must be prioritised. Specific operational priorities listed in the update included rapid ART initiation or continuation during cancer care, multidisciplinary management, monitoring for toxicity and drug–drug interactions, support to complete cancer treatment, and palliative care access. The release did not specify funding mechanisms or country-level implementation plans.
Next steps documented in the WHO release include continued collaboration with IARC to develop the HPV35 roadmap and the imminent publication of a technical policy brief. WHO did not give exact milestone dates for these outputs in the statement.
Limitations noted in the source: the update did not provide detailed programmatic models, disaggregated screening coverage by HIV status, or timelines for the HPV35 roadmap and technical brief. These remain unanswered implementation questions for programmes and policymakers.